Midgard Science

Labs / Assays & in vitro testing

Clyde Biosciences Cardiomyocyte Assay

Lanarkshire, United Kingdom · clydebio.com

Clyde Biosciences provides cardiomyocyte-based cardiac safety and cardiac drug discovery services for pharmaceutical and biotech companies. It uses human iPSC-derived and adult cardiomyocyte models to assess cardiotoxicity, proarrhythmic risk, and cardiac function from its site in Lanarkshire, Scotland, United Kingdom.

They take quote requests by email.

What they offer

  • CiPA Cardiac Safety Assessment

    Predicts proarrhythmic risk for IND submissions using a cardiomyocyte safety assay aligned with regulatory guidance.

  • Mechanistic Cardiovascular Toxicity Assay

    Measures voltage, calcium, and contractility during prolonged compound exposure to define cardiovascular risk and mechanisms of toxicity.

  • Heart Failure and Efficacy Assay

    Evaluates therapeutic candidates for heart failure using hiPSC cardiomyocytes and adult cardiomyocytes with functional readouts for efficacy and safety decisions.

  • hiPSC Cardiomyocyte Characterisation & Validation

    Benchmarks and validates hiPSC-derived cardiomyocytes for consistency, reliability, and suitability in cardiac safety and efficacy studies.

  • Voltage / Action Potential Analysis

    Captures high-resolution action potential data, including upstroke dynamics, to detect subtle electrophysiological changes.

  • Calcium Dynamics Analysis

    Measures calcium transients in human cardiomyocytes to assess excitation–contraction coupling and compound-induced dysfunction.

  • Contractility and Functional Assessment

    Quantifies cardiomyocyte contraction with high-frequency visual measurements to detect drug-induced changes in cardiac performance and negative inotropy.

  • In Silico Cardiac Modelling

    Integrates experimental data with computational models to improve prediction of human cardiac risk and support regulatory decision-making.

  • Custom Cardiac Safety and Efficacy Studies

    Provides tailored study design for specific cardiac liabilities from early discovery through IND-enabling programs.

  • Primary Screening Assay

    Screens larger batches of compounds for cardiovascular liability at hit-to-lead and lead optimisation stages using spontaneously beating hiPSC cardiomyocytes.

What they work on

Species and models
human iPSC-derived cardiomyocytes, adult cardiomyocytes, NCARDIA Cor 4U cell line
Assays and studies
cardiac safety assay, cardiotoxicity assay, proarrhythmic risk assay, mechanistic cardiotoxicity assay, heart failure efficacy assay, voltage assay, calcium assay, contractility assay, action potential analysis, in silico modelling
Instruments and platforms
voltage-sensitive dyes, patch-clamp quality electrophysiology
Scale and capacity
medium-throughput format
Therapeutic areas
cardiac safety, cardiac drug discovery, heart failure
Turnaround
Most of our standard projects are completed within 2-4 weeks
What to send
Compound collection from the client can be arranged · Cells can be delivered directly to the labs
Type
CRO
Sites
Newhouse, Lanarkshire, United Kingdom
Quality
FDA CiPA (validated CRO for the CiPA Assay) · Comprehensive In Vitro Proarrhythmia Ass (official core member) · FDA guidance (CiPA data for IND submission) · next-generation regulatory guidance (aligned services and platform) · New Approach Methodologies (NAMs) (human-relevant in vitro and in silico approaches)
Founded
2013

Similar labs. Aurigene Pharmaceutical Services, Bioneeds, EyeCRO, MedChem Partners

Found in a contract services directory. Listing built from clydebio.com. Work here? Claim this listing.

Clyde Biosciences Cardiomyocyte Assay · Midgard Science